Search hospitals > Quebec > MONTREAL
Hopital du Sacre Coeur de Montreal
Claim this profileMONTREAL, Quebec H4J 1C5
Global Leader in Breast Cancer
Conducts research for Asthma
Conducts research for Coronary Artery Disease
Conducts research for Kidney Disease
Conducts research for Colorectal Cancer
128 reported clinical trials
7 medical researchers
Summary
Hopital du Sacre Coeur de Montreal is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Asthma, Coronary Artery Disease, Kidney Disease, Colorectal Cancer and other specialties. Hopital du Sacre Coeur de Montreal is involved with conducting 128 clinical trials across 161 conditions. There are 7 research doctors associated with this hospital, such as Remi Goupil, MD MSc, Setareh Samimi, Isabelle Gingras, and Caroline Samson.Area of expertise
1Breast Cancer
Global LeaderStage I
HER2 negative
Stage II
2Asthma
Top PIs
Remi Goupil, MD MScHôpital du Sacré-Coeur de Montréal3 years of reported clinical research
Studies High Blood Pressure
Studies Kidney Disease
2 reported clinical trials
2 drugs studied
Setareh SamimiHopital Du Sacre-Coeur de Montreal4 years of reported clinical research
Studies Colon Cancer
Studies Colorectal Cancer
2 reported clinical trials
9 drugs studied
Isabelle GingrasCentre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal (CIUSSS NÎM) - Hôpital du Sacré-Coeur de Montréal1 year of reported clinical research
Studies Breast Cancer
1 reported clinical trial
5 drugs studied
Caroline SamsonHopital Du Sacre-Coeur de Montreal6 years of reported clinical research
Studies Mammogram
1 reported clinical trial
2 drugs studied
Clinical Trials running at Hopital du Sacre Coeur de Montreal
Chronic Kidney Disease
Kidney Disease
High Blood Pressure
Spinal Cord Injury
Spinal Fracture
Chronic Kidney Failure
Kidney Failure
Stroke
Bleeding
Atrial Fibrillation
Central vs Brachial Blood Pressure Targeting
for Chronic Kidney Disease
Background: Emerging data favors aortic blood pressure (BP) over brachial cuff BP in predicting CV and renal complications, as this BP directly impacts the heart, brain and kidneys. In parallel, central BP measuring devices have been developed that are more accurate towards aortic BP and easy to use without training. In no other condition than advanced chronic kidney disease (CKD) is BP control as important, since undertreatment is associated with adverse CV events and progression towards end-stage kidney disease (ESKD), while overtreatment similarly leads to adverse CV events and injurious falls but also acute kidney injury which can precipitate ESKD. To this day, standard BP management relies on brachial cuff BP, which is an imprecise surrogate marker of aortic BP, more so in the advanced CKD population. Considering that these patients have a high risk of CV morbidity and mortality and is a group where brachial BP may be the least reliable, it can be beneficial to manage hypertension in this population using central BP measurements. With the development of affordable and easy to use central BP devices, routine use of central BP in hypertension would now become a reality. However, the superiority of central BP to traditional brachial cuff BP in regard to clinical outcomes will first need to be demonstrated. Objectives: To demonstrate that targeting central BP in advanced CKD patients as opposed to brachial cuff BP is feasible and results in lower arterial stiffness after 12 months of follow-up. Methods: The CENTRAL-CKD trial is an investigator-initiated prospective parallel-group 1:1 randomized double-blinded multicenter pragmatic pilot trial. Patients with CKD stages 4 and 5 (n=116) will be randomized to either a central systolic BP target < 130 mmHg (intervention) or brachial systolic BP target < 130 mmHg (standard care). Central and brachial BP will be concomitantly measured, with treating physicians, patients and investigators blinded towards allocation. As this trial is of a pragmatic design, all other aspects of BP and CKD management, including anti-hypertensive treatment-related decisions, diastolic BP targets, and clinical and laboratory follow-ups will be at the discretion of the attending Nephrologist. The primary outcomes include feasibility of large-scale trial using prespecified criteria and aortic stiffness (carotid-femoral pulse wave velocity) at 12 months. Other cardiovascular, renal, quality of life and safety outcomes will be evaluated. Importance: CENTRAL-CKD is designed as a pilot trial aimed at providing the framework and justification to proceed to a large-scale trial with adequate power to detect the impact of the proposed intervention on clinically important outcomes.
Recruiting1 award N/A3 criteria
Central Blood Pressure Monitoring Devices
for Chronic Kidney Disease
The most accurate way to determine intra-aortic BP is to obtain invasive measures by vascular catheterization, which is not possible to perform routinely during the regular follow-up of patients. However, in recent years, devices used to estimate central BP have been designed and approved for clinical use. These devices can determine aortic BP in a non-invasive way using various techniques and algorithms and offer a high degree of precision when compared to invasive measurements of intraaortic BP. On the other hand, certain characteristics specific to the different devices mean that the central BP values obtained may not be interchangeable. It is therefore important to determine the degree of agreement of central BP values obtained using commercially available devices. This study aims to determine the degree of agreement between central BP measurements obtained using 4 devices commonly used to measure central blood pressure, i.e. Mobil-o-Graph NG (IEM, Germany), WatchBP Office (Microlife, Taiwan), Oscar 2 with SphygmoCor inside (SunTech, USA) and BP+ (Uscom, Australia). These four devices record the shape of the pulsatile wave and then derive the central BP using an algorithm. The main differences between these devices lie in this algorithm, or "transfer function,", which is unique to each and the calibration used. All use a brachial cuff to capture the pulse waveform and can easily be used in clinical practice.
Recruiting1 award N/A1 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Hopital du Sacre Coeur de Montreal?
Hopital du Sacre Coeur de Montreal is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Asthma, Coronary Artery Disease, Kidney Disease, Colorectal Cancer and other specialties. Hopital du Sacre Coeur de Montreal is involved with conducting 128 clinical trials across 161 conditions. There are 7 research doctors associated with this hospital, such as Remi Goupil, MD MSc, Setareh Samimi, Isabelle Gingras, and Caroline Samson.